Post Content
Is ESTA a good stock to buy? We came across a bullish thesis on Establishment Labs Holdings Inc. on Valueinvestorsclub.com by greenshoes93. In this article, we will summarize the bulls’ thesis on ESTA. Establishment Labs Holdings Inc.’s share was trading at $65.47 as of April 27th.
ESTA is a breast implant company focused on Motiva platform, with strong 2025 performance and optionality from innovation, US share gains, and operating leverage, supporting a $135 price target based on $9 EPS in 2028 at 15x multiple. Motiva SmoothSilk reduces capsular contracture via nano-surface reducing immune micromotion, enabling safer above-muscle placement and lowering rates to 1–1.5% versus high single digits, driving share gains globally.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Preserve uses Motiva implants with nesting technique preserving ligament structure reducing invasiveness enabling 35-minute local anesthesia procedures faster recovery and ~30% more visible volume increasing surgeon throughput and utilization. Mia is ultra-minimally invasive system for 1–2 cup enhancements using diamond-shaped implant improving projection and width performed in minutes under local anesthesia expanding TAM and consumer accessibility.
Culture emphasizes rapid innovation cycles with surgeons strong FDA differentiated platform first new PMA since 2013 while incumbents rely on bundling rather than product innovation. New Pfizer-exec CEO improves fragmented distributor network especially ROW enhances China channel access supporting mid-single digit international growth acceleration. Costa Rica free zone yields 0% tax through 2030 with NOLs implying long-term ~5% tax rate boosting cash flow.
Reconstruction market equal size to cosmetic but higher price FDA approval expected 2026–27 with existing off-label Motiva usage already in US hospitals. Modeling $5 EPS 2027 and $9 2028 driven by US share 40–65% OUS mid-single digit growth operating leverage with catalysts including US launch reconstruction approval distributor fixes and China upside supporting rerating to $135 at 15x multiple catalysts aligned ahead of rerating.
Previously, we covered a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad in May 2025, which highlighted strong immunology-led growth, Elahere oncology upside, and acquisition-driven pipeline expansion. ABBV’s stock price has depreciated by approximately 0.54% since our coverage. greenshoes93 shares a similar view but emphasizes ESTAs platform-led medical device innovation, surgical efficiency gains, and Motiva-driven TAM expansion within aesthetic healthcare devices.